CORRECTION

Correction: Individuals with *JAK1* variants are affected by syndromic features encompassing autoimmunity, atopy, colitis, and dermatitis

Michael E. Horesh, Marta Martin-Fernandez, Conor Gruber, Sofija Buta, Tom Le Voyer, Eve Puzenat, Harry Lesmana, Yiming Wu, Ashley Richardson, David Stein, Stephanie Hodeib, Mariam Youssef, Jacob A. Kurowski, Elizabeth Feuille, Luis A. Pedroza, Ramsay L. Fuleihan, Alexandria Haseley, Alain Hovnanian, Pierre Quartier, Jérémie Rosain, Georgina Davis, Daniel Mullan, O'Jay Stewart, Roosheel Patel, Angelica E. Lee, Rebecca Rubinstein, Leyla Ewald, Nikhil Maheshwari, Virginia Rahming, Ivan K. Chinn, James R. Lupski, Jordan S. Orange, Vanessa Sancho-Shimizu, Jean-Laurent Casanova, Noura S. Abul-Husn, Yuval Itan, Joshua D. Milner, Jacinta Bustamante, and Dusan Bogunovic

The authors regret that Fig. 2, Fig. 3, and Table 2 contained errors in the originally published article. In Fig. 2 (g–j), an open square in the graph key identifying "fLUC" samples has been removed because these panels contain no data representing fLUC samples. In the Fig. 3 (a–f) bar graph key, the open square was erroneously labeled; this has been corrected to "fLUC," and the label "WT" has been added to identify the black bars. In Table 2, "T" has been changed to "Y" in line 9 of the "Ultra-rare or rare Predicted GoF" row in the "(CADD)" column. The corrected figures and table are shown here, with the table correction indicated in red text. These corrections do not change the original conclusions of the article, and the figure legends remain unchanged. The errors appear in PDFs downloaded before April 30, 2024.

Figure 2

Figure 3

Figure 3. Panels a–c show Baseline IFI27, Baseline MX1, Baseline RSAD2; panels d–f show Induced IFI27, Induced MX1, Induced RSAD2. Relative mRNA levels (Log$_2$ FC over GAPDH). Legend: fLUC, WT, E139K, R506C, S700N, V985I, S703I.

Table 2. **In silico prediction of GoF activity in *JAK1* variants**

Variant class	*JAK1* variant		Predicted deleterious (Y/N)		Frequency, Bio*ME* (v1.2)
	Transcript	Protein	(CADD) (Rentzsch et al., 2019, Kircher et al., 2014)	(Sevim Bayrak et al., 2021)	$n = 30{,}814$
Exceedingly rare Severe GoF	c.1901C>A	p.Ala634Asp	Y (32)	Y (GoF)	Private, $n = 0$
	c.2108G>T	p.Ser703Ile	Y (26.1)	Y (GoF)	Private, $n = 0$
Ultra-rare or rare Mild-to-moderate GoF	c.415C>T	p.Glu139Lys	Y (22.6)	Y (GoF)	Private, $n = 0$
	c.1516C>T	p.Arg506Cys	Y (21.2)	Y (GoF)	5.63×10^{-04}, $n = 31$
	c.2099G>A	p.Ser700Asn	Y (25.1)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.2953G>A	p.Val985Ile	Y (18.2)	N (neutral)	1.82×10^{-04}, $n = 11$
					Total = 43 (0.14%)
Ultra-rare or rare Predicted GoF	c.287C>T	p.Thr96Ile	Y (21.7)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.296A>G	p.Asp99Gly	Y (23.3)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.379T>A	p.Trp127Arg	Y (25.4)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.779G>C	p.Ser260Thr	Y (20.4)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.1078C>T	p.Arg360Trp	Y (25.1)	Y (GoF)	4.97×10^{-05}, $n = 3$
	c.1439C>T	p.Thr480Ile	Y (22.5)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.1889A>G	p.Asp630Gly	Y (33.0)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.1951G>A	p.Val651Met	Y (27.6)	Y (GoF)	9.77×10^{-04}, $n = 59$
	c.2005T>G	p.Phe669Val	Y (28.2)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.2111A>G	p.Tyr704Cys	Y (27.2)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.2414T>A	p.Phe805Tyr	Y (29.7)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.2498A>G	p.Asn833Ser	Y (15.8)	Y (GoF)	1.36×10^{-03}, $n = 80$
	c.2617C>T	p.Arg873Cys	Y (32.0)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.2675G>A	p.Cys892Tyr	Y (24.8)	Y (GoF)	1.66×10^{-05}, $n = 1$
	c.3230A>G	p.Tyr1077Cys	Y (31.0)	Y (GoF)	4.97×10^{-05}, $n = 3$
					Total = 156 (0.51%)